Dyne Therapeutics (NASDAQ:DYN) Shares Down 3.3% - Time to Sell?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) dropped 3.3% during mid-day trading on Monday . The company traded as low as $13.78 and last traded at $13.94. Approximately 298,510 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 1,682,431 shares. The stock had previously closed at $14.41.

Wall Street Analysts Forecast Growth

DYN has been the topic of a number of recent research reports. Raymond James Financial initiated coverage on Dyne Therapeutics in a research note on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 target price on the stock. Robert W. Baird cut their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday. HC Wainwright cut their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Scotiabank initiated coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.93.

Dyne Therapeutics Price Performance

The business has a fifty day moving average of $11.54 and a 200-day moving average of $14.71. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.00 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics during the fourth quarter worth about $50,000. GAMMA Investing LLC increased its stake in Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after purchasing an additional 2,345 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Dyne Therapeutics by 378.6% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock worth $32,000 after purchasing an additional 2,446 shares in the last quarter. Quarry LP purchased a new position in Dyne Therapeutics in the 1st quarter worth about $47,000. Finally, Summit Investment Advisors Inc. increased its stake in Dyne Therapeutics by 9.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.